SLEDAI-SRI-50
- 技術應用
- PatientscreeningPatientassessment
- 詳細技術說明
- Aninnovative clinical tool for screening patients with Lupus
- *Abstract
-
Theassessment of disease activity in lupus depends on the use of standardized,reliable and validated indices. A number of measures have been developed toassess lupus disease activity.
TheSLEDAI 2000 (SLEDAI-2K) Responder Index 50 (SRI-50) is a novel index thatmeasures ≥50% in each of the 24 descriptors of SLEDAI-2K and generates a totalscore reflecting disease activity overall. The SLE Responder Index (SRI) hasbeen successfully used to identify responders in recent trials.
SRI-50is a novel reliable responder index derived from the SLEDAI-2K that wasinitially developed in 2009. This was followed up by further prospectivevalidation for SRI-50 over three, six and 12 months.
Inthe derivation of SLEDAI-2K, researchers were focused on describing diseaseactivity in the 24 descriptors of SLEDAI-2K as either present or absent. Thusan improvement in the SLEDAI-2K descriptors is captured when a manifestationhas completely resolved. In the currently adopted outcomes for the assessmentof disease activity in rheumatoid arthritis and psoriatic arthritis, animprovement is based on the decrease in the severity of the manifestations andthis is reflected by the decrease in the joint count and not necessarily acomplete resolution of arthritis.
Thisshould also be applied to lupus patients and lupologists need to be able tomeasure a clinically meaningful improvement in each of the manifestations in astandardized way.
SRI-50was developed and validated based on this principle and thus might improve andfacilitate the identification of responders in research studies and clinical trials.
- *Principal Investigation
-
Dr. Zahi Touma,Dr. Dafna Gladman and Dr. Murray Urowitz , University HealthNetwork
- *Publications
- Z. Touma et al, Lupus. 21 (2012) 1305-1311.Z. Touma et al, Rheumatology (Oxford). 51 (2012) 1814-1819.
- 國家/地區
- 美國
